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Cycin E overexpression, a negative prognostic factor in breast cancer with
strong correlation to oestrogen receptor status
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Summary Cyclin E is a GI cyclin which has been proposed to be one of the key regulators of the important
GI/S transition, and could consequently be a potential deregulated molecule in tumours. Recently, it has been
observed that cyclin E is overexpressed in a variety of malignancies including breast cancer and that several
isoforms of the protein exists. In this study we have characterised the cyclin E expression in 114 tumour
specimens from patients with primary breast cancer using Western blotting. Various expression of cyclin E was
observed among tumours and a group of 27 patients out of 100 patients with stage I-III disease, identified as
having tumours with high cycin E levels, had a significantly increased risk of death and relapse from breast
cancer (P=0.0002 and P=0.015 respectively). Even in the subgroup of axillary node-negative patients the
cyclin E level was of prognostic importance. There was also a strong association between cyclin E expression
and oestrogen receptor status (P<0.00001), and tumours with high cyclin E expression were in general
oestrogen receptor negative, suggesting a potential role for cyclin E in mechanisms responsible for oestrogen-
independent tumour growth.
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From being considered a disease with a long locoregional
stage, breast cancer is now recognised to disseminate early
during its course, which, in terms of therapy necessitates
consideration of the disease as potentially systemic at time of
diagnosis. To this end metastases to axillary lymph nodes,
tumour size and grade, oestrogen and progesterone receptor
status and tumour proliferation markers, have been used to
direct adjuvant therapy (Sigurdsson et al., 1990). During
recent years several biological parameters, such as cathepsin
D level in tumour tissue (Tandon et al., 1990) and gene
amplification of the proto-oncogene c-erbB2 (neu) (Slamon et
al., 1989), have been under evaluation for their capacity to
add new prognostic information, but a marker, or a
combination thereof, which can clearly predict whether a
patient will experience recurrence has still to be defined. Such
ideal prognostic factors would probably be central in the
disease pathogenesis, and their identification could most
likely give new insight into breast cancer oncogenesis.
Proliferation of normal cells is characterised by rigorous
control mechanisms surveying the orderly events leading to
DNA replication and mitosis, only allowing further advance
in the cell cycle if the previous stages have been executed
properly. In tumour cells deficiences in these control
mechanisms are important for initiating and exaggerating
the malignant phenotype (Hunter and Pines, 1994; Hartwell
and Kastan 1994). The ultimate molecules controlling the
cell cycle transitions are a family of protein kinases, the
cyclin-dependent kinases (cdks), which are regulated by
multiple mechanisms: the accumulation and binding of
cyclins, the displacement of inhibitors (such as p16, p21
and p27) and phosphorylation of the cdks by a cdk-
activating kinase (Draetta, 1994; Dulic et al., 1992; Xiong et
al., 1993; Tassan et al., 1994). Two cyclins, Dl and E, are
key regulators in the G, phase, cyclin E being a candidate
for controlling the GI/S transition (Koff et al., 1992) and
cyclin Dl of importance in emerging from quiescence and
for traversing the GI phase in response to mitogenic signals
(Matsushime et al., 1991). The above-mentioned catalytic
and regulatory molecules are potential targets for tumor-
igenesis because of their critical position in the cell cycle
(Hunter and Pines, 1994). The cdk4 gene has been shown to
be amplified in glioma cell lines (He et al., 1994) and the
p16 gene is mutated and inactivated in several cell lines and
lymphomas having the property of a tumour-suppressor
gene (Okamoto et al., 1994; Otsuki et al., 1995). Cyclin DI
was originally identified as a putative proto-oncogene
clonally rearranged in a subset of thyroid adenomas by a
chromosomal inversion placing the cyclin DI gene in close
proximity to the enhancer of the parathyroid hormone gene
leading to an overexpression of the cyclin gene product
(Motokura et al., 1991). Cyclin Dl gene rearrangements
have also been implicated in mantle cell lymphomas, in head
and neck, lung and bladder cancers (Williams et al., 1993;
Motokura and Arnold, 1993) and gene amplification of the
region lql3 encompassing the cyclin DI gene is found in
15-20% of patients with breast cancer and has been
associated with an unfavourable prognosis (Theillet et al.,
1990; Lammie et al., 1991; Schuuring et al., 1992).
Transgenic mice overexpressing cyclin Dl develop mam-
mary hyperplasia and adenocarcinoma (Wang et al., 1994),
placing cyclin Dl as an oncogene central in the tumorigen-
esis of a substantial portion of prevalent cancers.
Evidence for a role of cyclin E in oncogenesis is more
circumstantial than for cyclin DI, but deregulation of the
gene with overexpression of the protein has been described in
various malignancies, including breast cancer (Buckley et al.,
1993; Leach et al., 1993; Keyomarsi and Pardee, 1993). These
alterations seem to be specific for tumour cells and may
represent a true tumour-associated abnormality. In a limited
study on breast cancer specimens, overexpression of cyclin E
protein seemed to correlate with tumour aggressiveness as
determined by tumour stage and grade, suggesting a potential
role for cyclin E as a prognostic marker for breast cancer
(Keyomarsi et al., 1994). However, there are no studies where
the potential prognostic importance of cyclin E overexpres-
sion has been studied in a larger population of patients.
To gain further insight into the role of cyclin E in breast
cancer, we have analysed an archival material of 114 tumour
specimens from patients with stage I-IV disease for the
expression of cyclin E by Western blotting, correlated the
findings with established prognostic factors and evaluated the
prognostic significance.
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Patient data
The patient material in this study represents consecutively
treated women with primary breast cancer operated on at
Umea University Hospital during 1988-1991. Patients to be
included had a thorough clinical examination, bilateral
mammography, blood tests including liver parameters and a
chest radiograph. Ofthe 114 patients enrolled in the study, 14
patients were omitted from prognostic considerations because
of previously or newly diagnosed cancer in the opposite
breast (five patients), because of distant metastases at the
time of diagnosis (eight patients) or both (one patient).
Patients with distant metastases (stage IV) were treated
individually, others (stage I-III) were treated with curative
intent according to the guidelines recommended by the North
Swedish Breast Cancer Group. Briefly, local treatment
consisted of either mastectomy or a segmental resection
followed by radiation therapy to the remaining breast tissue.
Axillary dissection with histopathological examination was
performed in 101 patients, and if metastases were detected,
adjuvant therapy was given in the form of tamoxifen to post-
menopausal and chemotherapy or radiological castration
treatment to premenopausal patients. Elderly patients who
did not undergo axillary dissection were usually treated
adjuvantly with tamoxifen. If no axillary metastases were
detected, no further treatment was given. No patient received
any anti-tumoral therapy before surgery. Tumour classifica-
tion was in accordance with the International Union Against
Cancer.
Western blotting and cyclin E protein determinations
All tumour specimens were processed within 15 min after
surgery, and residual tumour tissue, collected after steroid
receptor analysis, was stored at -80°C. Tissue samples of
approximately 50 mg were homogenised and sonicated for
2 x 15 s in lysis buffer (0.5% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulphate (SDS), 50 mM
Tris-HCL pH 7.5, 150 mm sodium chloride with the protease
and phosphatase inhibitors: 20 jug ml-' leupeptin, 20 ,ug ml-'
aprotinin, 10 jug ml-' pepstatin, 1 mM phenylmethylsulpho-
nyl fluoride, 1 mM sodium fluoride and 1 mM EDTA) with
adequate cooling during the procedure. Samples were
centrifuged at 14 000 x g for 30 min at 4°C and aliquots of
the supernatant stored at -80°C until further analysis. Total
protein concentration was determined by the detergent-
compatible BCA (bicinchoninic acid) protein assay (Pierce,
IL, USA). Electrophoresis was performed on 10% SDS-
polyacrylamide gels using 40,g protein samples per lane
(Bio-Rad minigel system, Bio-Rad Lab, CA, USA) and
separated proteins transferred to nitrocellulose membranes
(Amersham, UK). Membranes were blocked in phosphate-
buffered saline containing 5% dried milk and 0.1% Tween-20
for 2 h and then probed by monoclonal mouse anti-cyclin E
antibodies (HE 12, Santa Cruz, CA, USA) diluted 1:1500 for
1 h. After washing, the membranes were incubated with
peroxidase conjugated anti-mouse antibodies (Amersham) for
1 h and proteins detected with an ECL (enhanced
chemiluminescent) detection system (Amersham) according
to the manufacturer's instructions. Separate gels were
employed for actin electrophoresis. Monoclonal mouse anti-
actin antibodies (Boehringer-Mannheim, Germany) diluted
1:5000 were used, otherwise, the conditions for the Western
blotting were as described above for cyclin E.
To be able to compare cyclin E concentrations between
different films, an equal amount of a protein standard,
prepared from the cell line BL-42 using the same protein
extraction procedure as stated above for tumour specimens,
was loaded on every gel with protein extracts from the
tumour specimens. Optical densities of the ECL films were
measured by a densitometer (Molecular Dynamics, CA,
USA), and relative protein concentrations were calculated
by dividing optical densities from tumour specimens by that
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of the BL-42 cell line standard. These normalised optical
densities from tumour specimens, hereafter denoted 'relative
cyclin E concentrations', were used as numerical variables in
the subsequent statistical analysis. The ECL detection system
gives accurate and reliable measurements of protein
concentrations within one order of magnitude (Kornblau et
al., 1994). To extend this range and ensure that the protein
determinations were performed in the linear range of the film,
three BL-42 protein standards diluted 1:1, 1:2 and 1:10, were
included on each gel and the films exposed for various times.
Comparisons between tumour samples and protein standards
were performed by using that film in which the optical
density between one of the protein standards and the tumour
sample did not differ by more than a factor of ten.
Oestrogen andprogesterone receptor measurement
Receptor content in tumour specimens was determined as
part of the routine clinical evaluation of the patients at the
time of diagnosis. Briefly, tumour tissue to be analysed was
selected by a pathologist, pulverised to homogeneity in liquid
nitrogen and suspended in a buffer. The homogenate was
centrifuged, the supernatant analysed for oestrogen and
progesterone receptor content by an enzyme immunoassay-
based system (Abbott Lab., IL, USA) and the pelleted
fraction analysed for DNA content by the method of Burton,
(1968). Receptor concentration was thereafter expressed as
fmol receptor per gg DNA, and tumours with a value lower
than 0.1 were considered receptor negative, those with a value
equal to or higher than 0.1 as receptor positive.
Tumour DNA ploidy evaluation
DNA ploidy evaluation was performed using flow cytometry
on deparaffinised tumour tissue sections as described
previously (Arnelov et al., 1990). DNA histograms were
classified as diploid/near-diploid when only one major Go/GQ
peak was detected, and as aneuploid when additional peaks
were identified.
Statistical methods
Associations between cyclin E levels and other parameters
were calculated using contingency tables and applying the X2
test or Fisher's exact test. The Kaplan-Meier method was
used in calculating survival curves, and comparison between
groups was performed with the log-rank test. Survival was
defined as the time elapsed from diagnosis to the appearance
of an event, considering either death owing to breast cancer
(disease-specific survival) or the occurrence of clinically
confirmed local, regional or distant relapse (relapse-free
survival). If no event occurred, the patient was censored at
the time of latest medical check-up, at the time of occurrence
of other malignancy or at the time of death caused by
intercurrent disease. Comparison of intervals from diagnosis
to occurrence of an event between two groups ofpatients was
performed using the Mann-Whitney U-test. Multivariate
analysis was performed with Cox's proportional hazards
model for censored data. All calculations were performed in
SPSS version 6.0 (SPSS, IL, USA).
Results
Cyclin E protein expression
A total of 114 tumour specimens from breast cancer patients
were analysed for cyclin E expression, 100 from patients with
unilateral stage I-III disease and 14 from patients with
actual or previously diagnosed cancer in the opposite breast
and/or with stage IV disease. Determinations of cyclin E
protein concentrations in tumour specimens were performed
by Western blotting and densitometric analysis as outlined
above. Representative Western blots and the corresponding
estimates of relative cyclin E protein concentrations, areCyclin E overexpression and breast cancer
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shown in Figure la and b. Besides the main cyclin E protein
with molecular weight of 49 kDa, a 43 kDa band as well as
several other bands with lower molecular weights were often
detected with various intensities relative to the main cyclin E
protein. As shown by others these bands represent various
biologically active isoforms of cyclin E and we therefore
included all detectable immunoreactive cyclin E proteins in
the densitometric measurements (Keyomarsi et al., 1995).
Cyclin E expression varied considerably among tumours,
some tumours exhibited about 200 times higher relative cyclin
E concentrations than others. The result of cyclin E analysis
of the 114 breast cancer samples is shown in Figure 2. Actin
was used as an internal control for equal cellular protein
loading among different samples on the gel, and we observed
only minor variation in the expression of actin (Figure lc).
a
Cyclin E
b
12
c
0
co L._
w 4-0
0
a
8 0
0
w C
ca
*1
11
10
4
3
2
1
0
10 ~~ ~ ~ ~ ~ L. v
-66
-45
-31
kDa
I I nF
17,.
-cut-off
d0
Determination of a cut-off levelfor cyclin E
To define an appropriate cut-off level for cyclin E in the
subsequent statistical analysis, a strategy would be to define
the extent of protein expression in normal breast tissue and
consider values above this range as tumour-associated
overexpression. Analysis of several specimens obtained from
breast reduction surgery revealed a low and often barely
detectable cyclin E expression (data not shown) in agreement
with a tight relationship between cell proliferation and cyclin
E expression and a generally low proliferative activity in
normal breast epithelium. Instead, we interpreted the cyclin E
expression among patients (Figure 2) as considerably skewed
and consisting of two populations, with a cut-off level near
0.5: one major population with low relative cyclin E
concentrations showing small variations and a minor
population with higher, but considerably more varied,
protein levels. The patients were accordingly divided into a
group with relative cyclin E concentrations below 0.5 and
into another group with relative concentrations equal to or
higher than 0.5, subsequently said to have 'low' or 'high'
cyclin E levels respectively.
Associations between cyclin E levels and other parameters
The 114 tumours from patients with stage I-IV breast cancer
disease were included in this part of the study. The above
selected cut-off level divided the material into a group of 80
patients (70.2%) having tumours with low cyclin E levels and
a group of 34 patients (29.8%) having tumours with high
cyclin E levels. Associations between cyclin E levels and other
biological and clinical parameters are shown in Table I. A
significant relationship existed (P=0.025) to tumour size,
with tumours classified as TI having high cyclin E levels in 8
of 46 (17.4%) cases in contrast to tumours classified as T2
and T3 having high cyclin E levels in 23 of 62 (37.1%) cases.
The distribution of disease stage showed no statistical
difference between the two cyclin E groups (P=0.071),
although a trend was observed in stage I disease towards
low cyclin E level. A strong association existed between cyclin
E levels and oestrogen receptor status (P<0.00001), receptor-
negative tumours having high cyclin E levels in 22 of 33
(66.7%) tumours as opposed to 11 of 80 (13.8%) receptor-
positive tumours. Conversely, of the 34 tumours with high
cyclin E levels 22 (64.7%) were oestrogen receptor negative,
and considering the 15 tumours with the highest relative
cyclin E concentrations, 14 (93.3%) were receptor negative.
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Figure 1 (a) Representative Western blot of protein extracts
from five breast cancer specimens (U176-U183) and a standard
(cell line BL-42) using monoclonal anti-cyclin E antibodies.
Molecular weights are indicated. The full length cyclin E mRNA
corresponds to a protein of 49kDa. The patients U178 and U181
were oestrogen receptor negative, while the other three patients
were receptor positive. (b) Densitometric cyclin E quantification
of tumour samples and the cell line standard from a. Protein
concentrations were expressed as relative to the cell line standard,
designated a relative protein concentration of 1. The ratio of
relative cyclin E concentrations between U178 and U177 was
approximately 200. (c) A Western blot of the same tumour
samples and cell line standard as in a using anti-actin antibodies.
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Figure 2 Histogram showing the results of cyclin E protein
quantification of 114 primary breast cancer samples. One patient
with relative cyclin E concentration higher than 5 was designated
a value of 5 in the graph to get a clearer illustration. The arrow
indicates the proposed cut-off level at a relative cyclin E
concentration of 0.5.
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Table I Associations between cyclin E expression and other biological and clinical parameters in
patients with stage I-IV disease
114 primary breast cancer
Low cyclin E High cyclin E
level level
Parameter (n=number ofpatients) (n=80) (n=34) P-value
Tumour size 0.025
pTl (<20mm) (n=46) 38 (82.6%) 8 (17.4%)
pT2, pT3 (>20mm) (n=62) 39 (62.9%) 23 (37.1%)
Not determined (n=6)
Lymph node status 0.33
pNO (n=53) 39 (73.6%) 14 (26.4%)
pN+ (n=48) 31 (64.6%) 17 (35.4%)
Not determined (n= 13)
Disease stage 0.071
I (n= 30) 26 (86.7%) 4 (13.3%)
II (n=63) 40 (63.5%) 23 (36.5%)
III (n=2) 2 (100.0%) 0 (0.0%)
IV (n=9) 5 (55.6%) 4 (44.4%)
Unknowna (n = 10)
Histological type 0.16
Ductal carcinoma (n=99) 68 (68.7%) 31 (31.3%)
Lobular carcinoma (n= 10) 9 (90.0%) 1 (10.0%)
Othersb (n =5)
Oestrogen receptorc <0.00001
Negative (n=33) 11 (33.3%) 22 (66.7%)
Positive (n=80) 69 (86.3%) 11 (13.8%)
Not determined (n= 1)
Progesterone receptorc <0.00001
Negative (n=44) 20 (45.5%) 24 (54.5%)
Positive (n=68) 60 (88.2%) 8 (11.8%)
Not determined (n =2)
Aneuploidy 0.095
Yes (n=56) 36 (64.3%) 20 (35.7%)
No (n=48) 38 (79.2%) 10 (20.8%)
Not determined (n = 10)
aPatientswithunknowndisease stage (owing tounknown T orNstatus) wereallwithoutdistantmetastases, i.e. wereeitherinstage
I, II or III. bHistological classification not possible or information missing. COestrogen and progesterone receptor categories as
defined in 'Materials and Methods'.
To illustrate this inverse relationship clearly, a plot of
oestrogen receptor concentrations vs relative cyclin E
concentrations as continuous variables is shown in Figure
3. A similar association as presented for the oestrogen
receptor existed between cyclin E levels and progesterone
receptor status (P<0.00001). Aneuploid tumours tended to
have higher cyclin E levels (20 of 56 tumours or 35.7%) than
diploid tumours (10 of 48 or 20.8%), although the difference
did not reach statistical significance (P=0.095). No
significant relationship was found between cyclin E levels
and lymph node status or histological type.
Breast cancer-specific and relapse-free survival
In the survival analysis only the 100 patients with unilateral
stage I-III disease were included. The same cut-off level of
0.5 was used because of a similar cyclin E distribution in
these patients. The patients were followed for a median
period of 53 months (23-80 months) and divided into groups
of 73 and 27 patients having tumours with low and high
cyclin E levels respectively. Univariate analysis of breast
cancer-specific survival showed that the group of patients
with high tumour cyclin E levels experienced an increased
risk (P=0.0002) of death owing to breast cancer compared
with patients with tumours expressing low cyclin E levels
(Figure 4). By varying the cut-off value for the relative cyclin
E concentration, statistical significance could be obtained in a
broad interval of values (0.25-1.7). The high cyclin E level
was moreover a risk factor in the subgroups of node-negative
and node-positive patients (P=0.001 and 0.037 respectively).
Nodal status and oestrogen and progesterone receptor status
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Figure 3 Oestrogen receptor concentrations vs relative cyclin E
concentrations. Oestrogen receptor and relative cyclin E
concentrations were truncated at values of 5 to get a clearer
illustration.
were in addition found to be risk factors (Table II). In
univariate analysis of relapse-free survival the cyclin E level
was found to be a significant risk factor for relapse
-1
00 00 0 00Cyclin E overexpression and breast cancer
NH Nielsen et al
878
(P=0.015, Figure 5). The interval from diagnosis to relapse
was shorter in the group of patients with high cyclin E levels
compared with the group with low cyclin E (median 21 vs 37
months respectively, P=0.004), but no significant difference
was found in the number of patients who experienced relapse
in the two groups. Oestrogen receptor status and tumour size
were additional risk factors for relapse (P=0.008 and
P=0.027 respectively, Table II).
In multivariate analysis of breast cancer-specific survival
with covariates showing statistical significance in the
univariate analysis, oestrogen receptor status and nodal
status turned out to be independent prognostic factors
(Table II). Neither of the significant risk factors found in
the univariate analysis of relapse-free survival was an
independent risk factor in multivariate analysis (Table II).
Discussion
Human cyclin E is a highly conserved protein that was first
identified by virtue of its ability to rescue GI-cyclin-defective
budding yeast (Koff et al., 1991). It is a candidate protein for
governing the progression of cells into S-phase because of
several distinctive features: (1) the amount of cyclin E and
cyclin E-cdk2 HI histone kinase activity increases during GI
and peaks near the GI/S boundary; (2) it has a short half-life
constituting the labile components that regulate the cdk2
kinase activity; (3) ectopic overexpression of the protein in
fibroblasts shortens the GI interval; and (4) microinjection of
antibodies against cyclin E in later part of GI blocks the
entry into the S-phase (Draetta, 1994; Dou et al., 1993;
Resnitzky et al., 1994). In vivo substrates for the cyclin E-
cdk2 kinase activity have not yet been fully determined but
the complex might collaborate with cyclin D -cdk4 to
phosphorylate and inactivate the retinoblastoma tumour-
suppressor protein pRb, thereby releasing sequestrated
transcription factors such as E2F that are important for the
regulation of proteins implicated in the GI/S transition and
the DNA synthesis (Weinberg, 1995).
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Overexpression of cyclin E has been observed in a variety
of tumours, including breast cancer cell lines and tissue
specimens, and given the central role for cyclin E in cell
division, it has been suggested that this may contribute to the
malignant phenotype, although no direct evidence exists that
cyclin E is an oncogene (Buckley et al., 1993; Leach et al.,
1993; Keyomarsi and Pardee, 1993; Keyomarsi et al., 1994;
Dutta et al., 1995). This overexpression seems to be tumour
specific and not merely a secondary event caused by increased
proliferation of tumour cells. In a study on breast cancer cell
lines, ten of ten expressed high levels of cyclin E when
compared with actively growing normal breast epithelial cells
(Keyomarsi and Pardee, 1993), and in another study using
breast cancer tissue, no correlation was found between
expression of cyclin E and that of proliferating cell nuclear
antigen (PCNA), a marker ofcell proliferation (Keyomarsi et
al., 1994).
Previously, studies using tumour cell lines and smaller
series of tumour specimens from patients, have defined
quantitative and qualitative alterations in cyclin E expression
in cancer cells, but no studies hitherto have been conducted
to examine the frequency and variability in cyclin E protein
expression in cohorts of patients and correlated the findings
with clinicopathological parameters and the disease outcome.
We have studied the cyclin E protein expression using
Western blotting, which offers quantitative measurement of
protein concentrations, but the method is susceptible to
dilution of the sample by protein from non-cancerous cells
and by varied amounts of extracellular stromal proteins,
giving a potentially inaccurate concentration ofproteins from
tumour cells. The actin control used in the material showed,
however, only small variations between samples, indicating
that the dilutional effects from extracellular proteins were
minor. These variations should be compared with the
prominent variation in cyclin E expression between
tumours. To investigate the cyclin E expression further in
breast cancer specimens we have initiated an immunohisto-
chemical study using the same antibody as in this study and
preliminary results show a quantitative agreement between
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Figure 4 Kaplan-Meier plot of breast cancer-specific survival in
100 patients with stage I-III disease.
Months after diagnosis
Figure 5 Kaplan-Meier plot of breast cancer relapse-free
survival in 100 patients with stage I-III disease.
Table II Disease-specific survival and relapse-free survival in 100 primary breast cancer patients with stage I-III disease
Disease-specific survival Relapse-free survival
Prognostic Univariate Multivariate Relative Univariate Multivariate Relative
factora analysis (P-value) analysis (P-value)" riskc analysis (P-value) analysis (P-value)b riskc
Tumour size 0.072 - - 0.027 0.12 1.89 (0.84-4.26)
Nodal status 0.016 0.023 3.27 (1.18-9.12) 0.37
Aneuploidy 0.48 - 0.53
Oestrogen receptor <0.0001 0.011 0.17 (0.04-0.67) 0.008 0.14 0.51 (0.21-1.25)
Progesterone receptor 0.006 0.58 1.43 (0.41-5.00) 0.75
Cyclin E level 0.0002 0.17 2.06 (0.72-5.84) 0.015 0.54 1.33 (0.53-3.35)
aCategories of the prognostic factors as defined in Table I. bOnly covariates showing statistical significance in the univariate analysis were
included in the multivariate model. cRelative risk corresponds to the multivariate analysis. Ninety-five percent confidence interval in parentheses.
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the two methods in determining the cyclin E expression in
tumour cells (NH Nielsen et al., manuscript under
preparation).
We could demonstrate a large variation in cyclin E protein
levels among tumour samples by a factor of 200, and
interestingly, the cyclin E expression was not found to be
normally distributed: about a quarter of the patients showed
substantiallty higher and more varied expression than the
rest, raising the possibility that different biological mechan-
isms may underlie the observed variation in cyclin E
expression. The finding of a very strong relationship between
high cyclin E levels and oestrogen receptor-negative status
may explain the prognostic signifia of cyclin E, but it
cannot be ruled out that the cyclin E level per se could give
additional prognostic information. The multivariate analysis
of breast cancer-spcific survival showed that it was the
oestrogen receptor status, not the cyclin E level, which
provided independent prognostic information, but our
statistical analyses might have been hampered by the
relatively small number of patients in the study, the strong
association between covariates and the confounding effect of
treatment; anti-hormonal treatment was used as an adjuvant
to receptor-positive patients in the study and as the foremost
drug in cases of recurrence with often favourable initial
responses. The cyclin E level was, in addition, a prognostic
factor for relapse, and for death in breast cancer in the
subgroups of lymph node-negative and -positive patients.
Further studies are necessary to place this new prognostic
marker for breast cancer in a clinical context; especially the
finding of cyclin E's prognostic significance in the clinically
important group of node-negative patients, of whom some
might benefit from adjuvant treatment, should be an
encouragement to further clinical investigations.
Although overexpression of cyclin E seems to be a true
tumour cell abnormality and not merely proliferation induced
as argued by others (Keyomarsi and Pardee, 1993; Keyomarsi
et al., 1995), this does not exclude the possibility that
tumours demonstrating high cyclin E expression have higher
fractions of proliferating cells than tumours with a low
protein expression. In a recently published immunohisto-
chemical study on breast tumours a significant correlation
was observed between the percentage ofcyclin E-positive cells
and the amount of cyclin cells determined by the Ki-67
antigen (Dutta et al., 1995). However, a lack of correlation
between the proliferative compartment and the amount of
cyclin E-positive cells was also observed in several breast
tumours suggesting that cyclin E is truly overexpressed in a
group of breast tumours. The strong association between
high cyclin E levels and receptor-negative tumours observed
in this study also suggests a correlation between the cyclin E
level and proliferation, since oestrogen receptor-negative
tumours have repeatedly been shown to have a higher
proliferation rate than receptor-positive tumours (Sigurds-
son et al., 1990; Feichter et al., 1988; Meyer and Province,
1994).
A remarkable result in the present study was the finding
that a considerable part of oestrogen receptor-negative
tumours expressed high cyclin E levels (22 of 33 tumours).
The oestrogen receptor is a nuclear protein that functions as
a transcription factor, regulating the expression of genes that
constitute parts of a complicated network of molecules
involved in control of cellular proliferation and differentia-
tion in response to oestrogenic hormones. Several molecules
in these pathways have been associated with increased
tumorigenicity and the progress of breast cancer to a
hormone-independent state (Horwitz, 1994; van Agthoven
et al., 1992; Herman and Katzenellenbogen, 1994). Our
finding raises the possibility that overexpression of cyclin E
could also be a potential operating mechanism to escape
hormone dependence by promoting S-phase entry without the
need for an oestrogenic stimulus. The mechanisms underlying
cyclin E protein overexpression have not yet been defined in
detail. The oestrogen receptor-negative breast cancer cell line
MDA-MB-157 exhibits an 8-fold amplification ofthe cyclin E
gene and a 64-fold overexpression of its mRNA that is
translated into several overexpressed proteins (Buckley et al.,
1993; Keyomarsi and Pardee, 1993), but whether amplifica-
tion ofthe cyclin E gene is a general event in breast cancer is
unknown. Increased stability of mRNA has been reported
(Keyomarsi and Pardee, 1993), and alterations on the
transcriptional level or upstream in the signal transducing
pathways could be involved.
Of the oestrogen receptor-negative tumours, not all
expressed high levels of cyclin E (11 of 33 tumours), and
conversely, not all tumours showing high cyclin E levels were
receptor negative (12 of 34 tumours), so the mechanisms
leading to overexpression of cyclin E and the relationship to
oestrogen receptor content may be complex and could
involve other important cell cycle regulator molecules. In
this context, cyclin DI is especially interesting, because
experiments using breast cancer cell lines have shown that
cyclin Dl expression is increased in response to mitogenic-
induced cell proliferation (Sutherland et al., 1993; Musgrove
et al., 1993, 1994), and that the way anti-oestrogens block the
cell cycle may involve down-regulation of cyclin Dl in GI
(Watts et al., 1994). Moreover, tumours exhibiting amplifica-
tion ofthe region 1 q13 encompassing the cyclin Dl gene are
often oestrogen receptor positive (Buckley et al., 1993;
Musgrove et al., 1994; Adnane et al., 1989), but the
regulation of the cyclin Dl gene and its role in oestrogen-
negative tumours has yet to be defined. Differential
deregulation of several crucial cell cycle control molecules
could possibly be implicated in hormone-independent breast
cancer and may explain why a minor group of oestrogen
receptor-negative patients in our study apparently had low
cyclin E expression.
In summary, we have demonstrated large variations in
cyclin E protein expression among tumours from patients
with primary breast cancer, identified cyclin E as a new
prognostic factor and could show a strong relationship
between cyclin E protein abundance and oestrogen recep-
tor-negative status, pointing to a possible role for cyclin E in
the mechanisms responsible for oestrogen hormone-indepen-
dent tumour growth. In our laboratory we currently study
the pattern of expression of several important cell cycle
regulators in oestrogen-positive and -negative tumours in the
hope of getting a more coherent picture of the observed
variations in cyclin expression and oestrogen receptor status,
which in the future could possibly be applied to classify
breast cancer according to the prevailing mechanisms of cell
cycle deregulation.
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